As of June 2, 2025, DiaMedica Therapeutics Inc (DMAC) reports a Gross Margin of 7775.20%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing DiaMedica Therapeutics Inc's Gross Margin to Peers
To better understand DiaMedica Therapeutics Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| DiaMedica Therapeutics Inc (DMAC) | 7775.20% |
| Protara Therapeutics Inc (TARA) | 7775.20% |
| Gracell Biotechnologies Inc (GRCL) | 7775.20% |
| Genprex Inc (GNPX) | 7775.20% |
| Marker Therapeutics Inc (MRKR) | 7775.20% |
| Axcella Health Inc (AXLA) | 7775.20% |
Compared to its competitors, DiaMedica Therapeutics Inc's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.